Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study
Transfusion · 2024
DOI: 10.1111/trf.17981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Marie-Pier Domingue und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs and Innovation, Héma-Québec, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Blood Donors, Hepatitis B, Hepatitis C, Sexual Behavior. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Background
Combining pathogen reduction technology (PRT) with blood screening may alleviate concerns over the risk of transfusion‐transmitted infections (TTI) and support changes in blood donor selection to potentially increase blood availability. This study aimed to estimate the residual risk of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) transfusion‐transmission in Canada after implementing PRT, while eliminating deferrals for sexual risk behaviors. Study Design and Methods A probabilistic approach that combined Bayesian networks with Monte Carlo simulations was used to estimate the risk of transfusing HIV‐, HBV‐, or HCV‐contaminated blood components. Different scenarios were considered to compare the current residual risk after PRT implementation, with and without donor deferral criteria for sexual risk behaviors. Donor profiles and blood component outcomes were simulated based on a literature review including the prevalence and incidence of HIV, HBV, and HCV in the Canadian blood donor population; the use of current blood screening assays; and HIV, HBV, and HCV blood donor viral loads.
Results
In the universal PRT scenario (i.e., with PRT/without deferral criteria), the estimated risks of HIV, HBV, and HCV transmission were significantly lower than those in the currently observed scenario (i.e., without PRT/with deferral criteria).
Conclusions
This risk model suggests that PRT for platelets and plasma (and eventually for RBCs when available) significantly reduces the residual risks of HIV, HBV and HCV transfusion‐transmission and could enable the removal of blood donor deferral criteria for sexual risk behaviors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Affairs and Innovation, Héma-Québec, Montreal, Quebec, Canada.
- Faculté des Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
- Epidemiology & Surveillance, Canadian Blood Services, Ottawa, Ontario, Canada.
- School of Epidemiology & Public Health, University of Ottawa, Ottawa, Ontario, Canada.
- Creative Testing Solutions, Tempe, Arizona, USA.
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Sheila F O'Brien, Yves Grégoire, Marion C Lanteri, Susan L Stramer, Antoine Lewin
Förderung
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Domingue, M. P., O'Brien, S. F., Grégoire, Y., Lanteri, M. C., Stramer, S. L., Camirand Lemyre, F., & Lewin, A. (2024). Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study. Transfusion. https://doi.org/10.1111/trf.17981
Vancouver
Domingue MP, O'Brien SF, Grégoire Y, Lanteri MC, Stramer SL, Camirand Lemyre F, et al. Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study. Transfusion. 2024. doi:10.1111/trf.17981
BibTeX
@article{Domingue2024,
author = {Domingue, Marie-Pier and O'Brien, Sheila F and Grégoire, Yves and Lanteri, Marion C and Stramer, Susan L and Camirand Lemyre, Félix and Lewin, Antoine},
title = {Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17981}
}
EUVIMED